Sareum Share Discussion Threads

[criticalthinker1] 25/8/2022 22:41

Who said a possible leak would come from Sareum Henry?
Things have changed somewhat since the Sierra Oncology takeover.
But let's just ignore that point Henry.
Hold my head in my hands with your posts and actually can't believe how naive your posts are.
PS hope your GCSE results received this week are what you hoped for.
If you did Biology I've got 6 questions for you.
1. What are the four building blocks of DNA?
2. What is the difference between DNA and RNA?
3. What role does tyrosine play within DNA?
4. What happens if tyrosine is replaced by RNA uracil?
5. Explain how cytokine storms and cytotoxicity can become an issue in the human body and what might cause them?
6. Give your opinion on what causes DNA damage and what companies you know have promising ipr tackling DDR (DNA Damage Repair) with ongoing drug trials.
Tyk tok Henry
Go on from someone who you say is clueless ..do me the gesture of responding. I have my blue pen and red pen ready...
Bet you don't because you are an echo chamber of ignorance and narcissistic tendencies.
Steadydanny

[gekko2023] 25/8/2022 21:31

CriticalStinker1 not just a username but a suggestion..cx

[horridhenry] 25/8/2022 13:59

wtf is the point of coming on and posting that ?
You claim to know a bit about this company ?
Then you will know that it doesn't leak
2 steps forward and 3 back from the expert

For anyone with an ounce of common sense take a look at the trading today which explains the rise

[criticalthinker1] 25/8/2022 11:32

Well sareum and val getting a lift...maybe short lived...maybe leak??

[criticalthinker1] 24/8/2022 20:40

Will do Norma. I've actually named it now...its called Henry.
On another note I read the Q and A and was pleasantly surprised that three of my posted were responded to. I did know that from listening to it but nice to see 3 questions in succession.
My take from Q and A and digestion and deliberation..
The old adage ...less is more!..it imo had some interesting points which I posted here straight after the q and a.
I think given the market capital and potentially the number of questions put forward by shareholders that 3 of mine written verbatum were responded to has given my steadydanny radar a comforting nights sleep.
Note Abbvie were part of the Boston conference!
I suspect Abbvie are talking to us whilst GSK think they have a backdoor to us via SRA737...who need to up their game...I suspect our BODs are having indirect conversations due to NDAs with our HNWIs as to 'what could be'.

[horridhenry] 24/8/2022 16:36

We have a Ukrainian Family living in one of our's

[norma_stitts] 24/8/2022 10:00

Danny, keep that runner going. I’ve eaten most of mine now.

I did find a courgette that had somehow managed to evade detection yesterday. It weighed in at 1.474kg, so is probably better described as a marrow now! 😂

[horridhenry] 24/8/2022 08:38

Deadfanny

Oh dear dead. Interesting file building of your baseless direct accusations and lies.

"invalidate worthwhile discussion"
Put up something worthwhile and it will get discussed. You will no doubt be aware that there are many other posters on here not bothering with you. Why is that then ?

The stock options you talk about will have expired when the t/o was agreed, unless they all got vested before takeover at a 39 cent per share profit = $37,521

[blackhorse23] 23/8/2022 23:28

I have increased my CURY (LSE) portfolio today , excellent company with NO DEBT , revenue growth 10% to 10.1 billion, free cash per shares 400p but share price 60p ..

[criticalthinker1] 23/8/2022 23:16

Anyone got a reason why Sierra would give 12 new employees share options post agreed GSK takeover

NEWS

Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

05/05/2022

SAN MATEO, Calif.--(BUSINESS WIRE)-- Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twelve new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals entering into employment with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

The employees received options to purchase a total 96,200 shares of Sierra’s common stock. The options have an exercise price of $54.61 per share, which is equal to the closing price of Sierra’s common stock on the date of grant. The options will vest and become exercisable as to 25% of the shares on the first anniversary of each recipient’s start date, and then will vest and become exercisable as to the remaining 75% of shares in 36 equal monthly installments following the first anniversary, subject to each employee’s continued employment with Sierra on such vesting dates. The options are subject to the terms and conditions of Sierra’s 2018 Equity Inducement Plan, and the terms and conditions of the stock option agreement covering each grant.

Given momo is a given ...so 12 new employees get this offer and Sierra are effectively momo SRA737 and AZD5153...the last one part owned by AstraZeneca who have a certain law case against...! Not doing the groundwork for Henry as I've posted it already.. but it's old news apparently...despite never reading it on here or lse before.

So effectively SO got 12 new employees post GSK approved t/o when momo is good to go and SRA737 is a nothing who will do what Henry...i believe you said give it back...lmfao...
Seriously think this share should be above £5 even before CTA is RNSd as towards its pecidillos and maybe 'partners'
Best wishes to all Steadydanny

Runner Bean update. Just over 18.5 inches! Nettle soup working wonders.
Watch this space...

[criticalthinker1] 23/8/2022 21:00

Henry maybe check out WIPs post on lse at 1954 hrs. You will have noticed I have mentioned this and other previous ongoings before...but you think its all priced in and been discussed (discussion btw is domething you are incapable of..you just spout old news...means nothing...priced in) ..and ive never read one bit of research from you...not once..and yet the share price sinks so your priced in opinion goes out the window...so what price is your floor then?
Seriously think you need to filter yourself...words of wisdom for you..in order to go forward its always wise to keep one eye on the past.
Serious question are you working for PH? Trying to invalidate worthwhile discussion and noteable past info? History is still being learnt from the past.
There was a chap who believed he knew best. Ended badly for him in 1945.
Have you ever undertaken your family tree and see if you are related to an Austro-Hungarian cobbler?

[horridhenry] 23/8/2022 11:13

We have 27.5% of SR737, and no negotiating rights
Whatever is decided about it's future is out of our hands
Pointless getting hung up on it

The market clearly isn't bothered, there are bigger fish to fry, and as ever deadfanny you are miles behind everyone else.

Everything you post is either a copy and paste or ancient stuff already discussed to exhaustion. You bring nothing new.

Why not do your research like most sensible people and only post what you think is unique, or worthy of us long term holders.

[criticalthinker1] 22/8/2022 21:37

And politely Henry re Momelotinib this is the US MARKET.
Myelofibrosis is a fatal disorder of the bone marrow where fibrous scar tissue gradually replaces normal bone marrow, limiting its ability to make blood cells (haematopoiesis). This may cause anaemia (reduced red blood cells), leading to shortness of breath or fatigue; increased risk of infection due to decreased white blood cells; or increased risk of bleeding or bruising due to reduced platelet counts. Organs such as the spleen or liver may start to produce blood cells. This is known as extramedullary haematopoiesis, which causes splenomegaly or hepatomegaly (enlarged spleen or liver). Myelofibrosis affects approximately 20,000 patients in the US.

SO GSK BOUGHT SIERRA ONCOLOGY FOR THE ABOVE-MENTIONED NUMBER OF INDIVIDUALS IN THE US!!
FFS 20000 PATIENTS GARNERS GSK TO BUY SIERRA ONCOLOG FOR MOMELOTINIB!
I think anyone with grey matter can see Momelotinib was a screen for the SRA737 that has been tested in different countries so as not to give against a certain contract. Norma stitts pointed this out.
And quite correct.
If you seriously believe that GSK bought SIERRA for Momelotinib you are deranged. Luke Miels wants early oncology.
Tyk tok.

[criticalthinker1] 22/8/2022 18:30

I have unfiltered you HH. Read your posts. Assume you are in a pharma company as you are interested in drug research and have built a knowledge around that.
So you are looking forward to your next covid vaccine injection. How many more of those are you looking forward to?
And I see you bang the drum about myself being ousted from lse. Yet I was one of the top posters but got culled due to questioning the Telegram Group requirements James set up.
Funny that and that's your ammo.
PS Henry food for thought..if covid was so bad and whitty said flu disappeared (cough) and it mainly affected the weak and vulnerable..yet we need to jab all children..why are the Office of National Statistics now reporting excess deaths higher than pre covid?
You would have thought given the covid deaths excess deaths would reduce.
But get that vaccine that has had its definition changed..such as Bidens definition of recession where he thinks 97% of CEOs are wrong in believing a recession is occurring.
On a serious note I appreciate you do try to put me down..I hope its your self critical thinking and research that proves you right and me wrong..and not you being ego massaged by others because you do as they tell you.
I wish you well Henry. Sincerely.

[horridhenry] 22/8/2022 09:19

DEADFANNY

you are much better off measuring your bean every day, although it is amusing looking at the nonsense that you are churning out.

Looking forward to my next covid jab very soon

[criticalthinker1] 20/8/2022 22:26

Oh and as Mr Miels picks up on multiple myeloma...the last part of previous post ..gotta love this re our CTA application ....you can find it yourself but I'm

Because multiple myeloma is an immune disorder, as is psoriasis, the HealthTree for Multiple Myeloma research team evaluated connections between the two dieases after learning from HealthTree Cure Hub data that psoriasis was the most prevalent co-immune system condition for myeloma patients.13 May 2022

Sleep well those with golden tickets.
Steadydanny.

Runner bean update..just over 17 inches!

[horridhenry] 20/8/2022 11:27

Utter nonsense from the board fool. Top people in big cos. Move all the time, and being the USA there is always litigation that accompanies a move.
Nothing will be huge you copy and paste nutter

[criticalthinker1] 19/8/2022 22:31

Fierce pharma 16th August 2022 note the names..and individuals..that abcde report of Sierra Oncology/GSK purchase negotiation part of this..some sh1t hitting the fan and SRA737 is definitely part of this and maybe other licences...Mr miels ...naughty boy I believe...AZD5153 part of it..popcorn at the ready!!! Big time!!!!

An executive tug of war is brewing across the pond.

Angling to keep trade secrets out of a local rival’s hands, AstraZeneca has asked a London court to enforce and extend a noncompete agreement signed by a former employee who recently jumped ship to GSK, Bloomberg News reports.


The move is an effort by AZ to block Chris Sheldon—formerly the British Big Pharma’s vice president of investor relations—from sharing key therapeutic information with new employer GSK, according to the news service.

AstraZeneca did not respond to a request for comment by press time. 


GSK declined to comment on the litigation, but the company confirmed it had hired Chris Sheldon as SVP of GSK’s commercial portfolio. The hire “supports [GSK’s] clear ambition to invest in our commercial capabilities to deliver future growth,” a spokesperson said.

Sheldon’s role at GSK begins in September. During his time at crosstown competitor AstraZeneca, Sheldon had access to confidential information in a range of sensitive areas including oncology, AstraZeneca said in a legal filing seen by Bloomberg. According to the news service, Sheldon was paid more than 644,000 pounds sterling ($774,090) in company shares back in 2021 to sign the noncompete clause.

The noncompete agreement bars Sheldon from facilitating competition in respiratory, oncology and COVID-19-related therapy work for six months after leaving AZ, the company told Bloomberg.

Sheldon’s entry into the GSK fold coincided with that of another AZ employee, Garrett Rhyasen, who’s joining the rival company as VP of search and evaluation for oncology. The move represents a promotion for Rhyasen, who most recently worked in a similar capacity for AstraZeneca as executive director and global head of oncology search and evaluation, business development and licensing.

It isn’t unprecedented for AstraZeneca to tussle over exec departures. Back in 2017, the drugmaker sued Luke Miels, who’d also left for GSK, arguing that the former executive planned to start his stint at GSK “in breach of his contract of employment” with AstraZeneca, an AZ spokesperson told Fierce Pharma at the time.

Miels’ departure was mired in animosity. AstraZeneca accused Miels of misusing confidential info and documents to nab the top pharma job at GSK, while Miels claimed AstraZeneca chief executive and former mentor Pascal Soriot took his departure personally, threatening Miels over his visa when he turned down a counteroffer to stay, according to reports at the time.

Oh my this is going to be huge